Cofactor Genomics Appoints Renowned Oncologist Dr. Howard H. Bailey as Chief Medical Officer to Advance Precision Immunotherapy Diagnostics
Cofactor Genomics, a commercial-stage diagnostics company focused on advancing precision oncology through RNA-based predictive testing, has announced the appointment of internationally recognized oncologist and cancer researcher Howard H. Bailey, M.D., as its new Chief Medical Officer (CMO). The appointment marks a significant milestone for the company as it continues to expand the clinical adoption of its RNA-based biomarker platform and strengthen its position in the rapidly growing field of personalized cancer care.
Dr. Bailey brings more than three decades of experience in oncology, clinical research, academic medicine, and cancer center leadership. Throughout his distinguished 36-year career, he has played an instrumental role in advancing cancer prevention, developing innovative treatment strategies, leading multi-institution clinical research collaborations, and improving patient access to cutting-edge therapies. His appointment comes as Cofactor Genomics accelerates the commercialization of its flagship diagnostic platform, OncoPrism®, while expanding its clinical evidence across multiple cancer types.
Strengthening Clinical Leadership During a Period of Growth
As Chief Medical Officer, Dr. Bailey will oversee the company’s clinical strategy and help guide the broader integration of predictive biomarker testing into routine oncology practice. His leadership will focus on ensuring that RNA-based diagnostics become an increasingly important component of immunotherapy treatment selection, enabling physicians to make more informed therapeutic decisions for patients with cancer.
Among his primary responsibilities will be expanding the clinical evidence supporting OncoPrism in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), two cancer types in which immunotherapy has become a standard treatment option. He will also help shape clinical development programs in additional tumor indications as Cofactor continues to broaden the application of its RNA-based technology.
Beyond clinical research, Dr. Bailey will work closely with healthcare providers, academic institutions, payers, and professional guideline organizations to promote broader understanding and adoption of predictive biomarker testing. His efforts will include physician education initiatives, engagement with healthcare systems, and the integration of OncoPrism into both academic medical centers and community oncology practices.
Expanding the Role of Precision Oncology
Cancer treatment has evolved dramatically over the past decade, particularly with the introduction of immune checkpoint inhibitors that harness the body’s immune system to recognize and destroy cancer cells. While these therapies have transformed outcomes for many patients, not everyone responds equally to immunotherapy.
Determining which patients are most likely to benefit remains one of the biggest challenges in oncology today. Existing biomarkers, such as PD-L1 expression and tumor mutational burden, provide useful information but often fail to fully capture the complexity of interactions between tumors and the immune system.
Cofactor Genomics has developed an alternative approach through RNA-based molecular diagnostics that evaluate the biological activity of the tumor immune microenvironment rather than relying on a single biomarker.
The company’s flagship diagnostic, OncoPrism, analyzes patterns of RNA expression to predict whether patients are likely to respond to immune checkpoint inhibitors. This functional assessment offers physicians additional information that may improve treatment selection and reduce unnecessary exposure to therapies unlikely to provide benefit.
CEO Highlights Clinical Expertise
Chris Parker, Chief Executive Officer of Cofactor Genomics, described Dr. Bailey’s appointment as an important step in the company’s evolution from scientific innovation to widespread clinical implementation.
According to Parker, Dr. Bailey has built a career around translating promising scientific discoveries into practical improvements in patient care. His extensive experience leading clinical research networks, designing biomarker-driven studies, and collaborating with oncologists across diverse healthcare settings positions him well to help expand the clinical utility of Cofactor’s technology.
Parker noted that the company’s mission is to provide physicians with meaningful predictive information at critical treatment decision points. He emphasized that Dr. Bailey’s guidance will help ensure the company’s evidence generation efforts, healthcare system integration, and expansion into new cancer indications remain focused on improving patient outcomes.
Dr. Bailey Sees Opportunity to Improve Immunotherapy Selection
Dr. Bailey expressed enthusiasm about joining Cofactor Genomics during a period of rapid advancement in precision oncology.
He noted that immunotherapy has fundamentally changed cancer treatment over the past decade, offering long-lasting responses for many patients who previously had limited therapeutic options. However, clinicians continue to face uncertainty when determining which patients are most likely to benefit from these treatments.
According to Dr. Bailey, Cofactor’s RNA-based platform offers a compelling alternative to traditional biomarker strategies because it evaluates the broader complexity of the tumor immune environment rather than depending on a single molecular marker.
He stated that he looks forward to helping translate the company’s growing body of clinical evidence into practical clinical workflows that expand patient access while supporting physicians in making more personalized treatment decisions.
Distinguished Career in Academic Oncology
Prior to joining Cofactor, Dr. Bailey served for many years at the University of Wisconsin School of Medicine and Public Health, where he held multiple leadership positions before retiring in January 2025.
His responsibilities included serving as Associate Dean for Oncology and Professor of Medicine while overseeing numerous cancer-related initiatives throughout the university system. He also directed philanthropic efforts supporting cancer research and played an important leadership role within UW Health’s Cancer Service Line.
Perhaps most notably, Dr. Bailey served as Director of the University of Wisconsin Carbone Cancer Center, one of the nation’s leading comprehensive cancer centers recognized by the National Cancer Institute.
During his tenure, he helped strengthen the institution’s research capabilities while expanding collaborations between laboratory scientists, clinicians, and healthcare systems.
Extensive Experience in Clinical Research
Throughout his career, Dr. Bailey has participated in hundreds of cancer clinical trials spanning virtually every stage of therapeutic development.
He has served as principal investigator or study chair on more than 50 Phase I, II, and III clinical studies sponsored by either industry partners or federal agencies.
His expertise extends across early drug development, biomarker research, cancer prevention, and precision medicine.
In addition to directing clinical trials, Dr. Bailey served as principal investigator of the National Cancer Institute-sponsored University of Wisconsin Chemoprevention Consortium, which focused on developing strategies to reduce cancer risk before disease develops.
His work has contributed significantly to understanding how biomarkers can guide therapeutic decision-making while advancing personalized treatment strategies.
Leadership Across National Research Organizations
Dr. Bailey’s influence extends well beyond individual clinical trials.
Throughout his career, he has chaired or participated in numerous scientific committees associated with major organizations including:
- The National Cancer Institute (NCI)
- The American Society of Clinical Oncology (ASCO)
- The American Association for Cancer Research (AACR)
He also helped establish and lead multiple independently funded regional and national clinical research networks that facilitate collaboration among cancer centers, investigators, and healthcare institutions.
These collaborative initiatives have enabled broader participation in clinical studies while accelerating the evaluation of promising new cancer therapies.
National Recognition for Leadership
Dr. Bailey’s contributions to oncology have been recognized through numerous professional honors.
In 2025, he received the Big Ten Cancer Research Consortium Distinguished Leadership Award, acknowledging his longstanding commitment to advancing collaborative cancer research and his leadership in building multi-institution clinical research programs.
The award reflects decades of dedication to improving cancer treatment through scientific innovation, physician collaboration, and patient-centered clinical investigation.
OncoPrism Continues to Gain Clinical Momentum
Dr. Bailey joins Cofactor during a period of substantial commercial and clinical expansion.
The company’s OncoPrism platform has already achieved an important reimbursement milestone by receiving national Medicare coverage for patients with head and neck cancer.
This coverage expands access to predictive biomarker testing for eligible Medicare beneficiaries and supports broader adoption of precision immunotherapy selection.
At the same time, Cofactor recently reported findings from a large clinical study involving 1,487 patients with non-small cell lung cancer.
The study demonstrated that OncoPrism functions as a predictive biomarker for identifying patients likely to benefit from immune checkpoint inhibitor therapy.
Given that NSCLC represents the largest global indication for immune checkpoint inhibitors, these findings significantly expand the commercial and clinical potential of the company’s diagnostic platform.
Strategic Investments Supporting Expansion
Cofactor’s continued growth has also been strengthened through strategic investments from major healthcare organizations, including Labcorp and Ascension Ventures.
These investments are supporting several key initiatives, including:
- Expansion of patient access to predictive diagnostics
- Generation of additional clinical evidence across multiple cancer types
- Integration of OncoPrism into healthcare systems
- Scaling commercial operations
- Expansion of laboratory capacity
- Development of additional RNA-based predictive diagnostics
The company plans to leverage these resources to further establish predictive biomarker testing as a routine component of precision oncology.
The appointment of Dr. Howard H. Bailey as Chief Medical Officer represents an important step in Cofactor Genomics’ mission to transform immunotherapy treatment selection through RNA-based diagnostics. His extensive background in oncology research, clinical trial leadership, biomarker development, and academic medicine provides valuable expertise as the company expands the clinical adoption of OncoPrism and advances its broader precision oncology portfolio.
With growing clinical validation, expanding reimbursement coverage, and increasing support from strategic healthcare partners, Cofactor is well positioned to accelerate the integration of predictive RNA-based testing into routine cancer care. Under Dr. Bailey’s clinical leadership, the company aims to strengthen the evidence supporting its technology while helping physicians deliver more personalized immunotherapy decisions that improve outcomes for patients across multiple cancer indications.
About Cofactor Genomics
Cofactor Genomics is a commercial-stage diagnostics company that bridges the precision medicine gap by decoding RNA to solve the biggest problems in healthcare. Cofactor unlocks RNA’s potential as a transformational barometer of health using patented Gene Expression Classifiers (GEC). GECs go beyond gene mutation panel tests, using the latest advancements in machine learning and RNA to create Cofactor’s high-dimensional RNA models of biology, disease, and therapy response.
Cofactor’s pioneering work in RNA-based diagnostics has been published in The Journal for ImmunoTherapy of Cancer, The Journal of Molecular Diagnostics, and recognized by Nature Scientific Reports as breakthrough work in cancer. Cofactor is partnered with doctors and healthcare systems to bring precision medicine to cancer care. Cofactor’s OncoPrism is CAP/CLIA-validated and Medicare-approved. Learn more from www.cofactorgenomics.com and LinkedIn.